8DMH

Lymphocytic choriomeningitis virus glycoprotein in complex with neutralizing antibody M28

8DMH の概要

• エントリーDOI: 10.2210/pdb8dmh/pdb
• EMDBエントリー: 27538
• 分子名称: Glycoprotein G1, 18.5C-M28 Fab Light Chain, 18.5C-M28 Fab Heavy Chain, ... (7 entities in total)
• 機能のキーワード: viral glycoprotein, arenavirus, lcmv, gp, antibody, neutralization, viral protein, viral protein-immune system complex, viral protein/immune system
• 由来する生物種: Lymphocytic choriomeningitis virus; 詳細
• タンパク質・核酸の鎖数: 12
• 化学式量合計: 353269.35

構造登録者

Moon-Walker, A.,Hastie, K.M.,Zyla, D.S.,Saphire, E.O. (登録日: 2022-07-08, 公開日: 2023-04-12, 最終更新日: 2024-10-23)

主引用文献

Moon-Walker, A.,Zhang, Z.,Zyla, D.S.,Buck, T.K.,Li, H.,Diaz Avalos, R.,Schendel, S.L.,Hastie, K.M.,Crotty, S.,Saphire, E.O.
Structural basis for antibody-mediated neutralization of lymphocytic choriomeningitis virus.
Cell Chem Biol, 30:403-411.e4, 2023

PubMed Abstract: The mammarenavirus lymphocytic choriomeningitis virus (LCMV) is a globally distributed zoonotic pathogen that can be lethal in immunocompromised patients and can cause severe birth defects if acquired during pregnancy. The structure of the trimeric surface glycoprotein, essential for entry, vaccine design, and antibody neutralization, remains unknown. Here, we present the cryoelectron microscopy (cryo-EM) structure of the LCMV surface glycoprotein (GP) in its trimeric pre-fusion assembly both alone and in complex with a rationally engineered monoclonal neutralizing antibody termed 18.5C-M28 (M28). Additionally, we show that passive administration of M28, either as a prophylactic or therapeutic, protects mice from LCMV clone 13 (LCMV) challenge. Our study illuminates not only the overall structural organization of LCMV GP and the mechanism for its inhibition by M28 but also presents a promising therapeutic candidate to prevent severe or fatal disease in individuals who are at risk of infection by a virus that poses a threat worldwide.

PubMed: 36990092
DOI: 10.1016/j.chembiol.2023.03.005

実験手法

ELECTRON MICROSCOPY (3.19 Å)